Chongrui Xu

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/4059048/publications.pdf

Version: 2024-02-01

64 papers	3,964 citations	361045 20 h-index	161609 54 g-index
71 all docs	71 docs citations	71 times ranked	4940 citing authors

#	Article	IF	Citations
1	Phase I/Ib dose-escalation study of avelumab in Chinese patients with advanced solid tumors. Future Oncology, 2022, , .	1.1	0
2	Clinical utility of next-generation sequencing-based ctDNA testing for common and novel ALK fusions. Lung Cancer, 2021, 159, 66-73.	0.9	17
3	Complex ALK Fusions Are Associated With Better Prognosis in Advanced Non-Small Cell Lung Cancer. Frontiers in Oncology, 2020, 10, 596937.	1.3	21
4	HER2-Mediated Internalization of Cytotoxic Agents inERBB2Amplified or Mutant Lung Cancers. Cancer Discovery, 2020, 10, 674-687.	7.7	149
5	Familial association of lung cancer with liver cancer in first-degree relatives . Cancer Management and Research, 2019, Volume 11, 5813-5819.	0.9	1
6	Intratumoral heterogeneity of EGFR-activating mutations in advanced NSCLC patients at the single-cell level. BMC Cancer, 2019, 19, 369.	1.1	13
7	Analysis of resistance mechanisms to abivertinib, a third-generation EGFR tyrosine kinase inhibitor, in patients with EGFR T790M-positive non-small cell lung cancer from a phase I trial. EBioMedicine, 2019, 43, 180-187.	2.7	30
8	The spatiotemporal evolution of EGFR C797S mutation in EGFR-mutant non-small cell lung cancer: opportunities for third-generation EGFR inhibitors re-challenge. Science Bulletin, 2019, 64, 499-503.	4.3	6
9	A randomised phase II clinical trial of nab-paclitaxel and carboplatin compared with gemcitabine and carboplatin as first-line therapy in advanced squamous cell lung carcinoma (C-TONG1002). European Journal of Cancer, 2019, 109, 183-191.	1.3	13
10	Genomic Characterization of ERBB2-Driven Biliary Cancer and a Case of Response to Ado-Trastuzumab Emtansine. JCO Precision Oncology, 2019, 3, 1-9.	1.5	23
11	P1.01-85 Treatment for Advanced NSCLC with EGFR Mutations and De Novo MET Amplification/Overexpression. Journal of Thoracic Oncology, 2019, 14, S393.	0.5	0
12	Efficacy of ramucirumab and docetaxel given either before or after immune checkpoint inhibitors in patients with lung cancers.. Journal of Clinical Oncology, 2019, 37, 9078-9078.	0.8	4
13	Unique genetic profiles from cerebrospinal fluid cell-free DNA in leptomeningeal metastases of EGFR-mutant non-small-cell lung cancer: a new medium of liquid biopsy. Annals of Oncology, 2018, 29, 945-952.	0.6	197
14	EGFR mutations in earlyâ€stage and advancedâ€stage lung adenocarcinoma: Analysis based on largeâ€scale data from China. Thoracic Cancer, 2018, 9, 814-819.	0.8	42
15	P1.01-99 Detecting HER2 Alterations by Next Generation Sequencing (NGS) in Patients with Advanced NSCLC from the United States and China. Journal of Thoracic Oncology, 2018, 13, S502.	0.5	4
16	Liquid biopsy guided precision therapy for lung cancers. Journal of Thoracic Disease, 2018, 10, S4173-S4175.	0.6	3
17	JCSE01.09 Cluster Trial: Ph2 Biomarker-Integrated Study of Single Agent Alpelisib, Capmatinib, Ceritinib and Binimetinib in advNSCLC. Journal of Thoracic Oncology, 2018, 13, S311-S312.	0.5	2
18	P1.03-34 Combined Molecular and Radiological Evaluation Unveils Three Subtypes of Disease Progression to a Third Generation EGFR TKI. Journal of Thoracic Oncology, 2018, 13, S524-S525.	0.5	0

#	Article	IF	Citations
19	MA15.06 Circulating Tumor DNA Portrays the Resistance Landscape to a Novel Third Generation EGFR Inhibitor, AC0010. Journal of Thoracic Oncology, 2018, 13, S408-S409.	0.5	1
20	Afatinib versus gemcitabine/cisplatin for first-line treatment of Chinese patients with advanced non-small-cell lung cancer harboring EGFR mutations: subgroup analysis of the LUX-Lung 6 trial. OncoTargets and Therapy, 2018, Volume 11, 8575-8587.	1.0	21
21	Refining actionable HER2 alterations in lung cancers through next generation sequencing (NGS).. Journal of Clinical Oncology, 2018, 36, e24181-e24181.	0.8	0
22	Familial association of lung cancer patients with liver cancer in first-degree relatives.. Journal of Clinical Oncology, 2018, 36, e13597-e13597.	0.8	0
23	A phase III randomised controlled trial of erlotinib vs gefitinib in advanced non-small cell lung cancer with EGFR mutations. British Journal of Cancer, 2017, 116, 568-574.	2.9	155
24	Supraclavicular lymph node incisional biopsies have no influence on the prognosis of advanced non-small cell lung cancer patients: a retrospective study. World Journal of Surgical Oncology, 2017, 15, 12.	0.8	2
25	Acquired MET Y1248H and D1246N Mutations Mediate Resistance to MET Inhibitors in Nonâ€“Small Cell Lung Cancer. Clinical Cancer Research, 2017, 23, 4929-4937.	3.2	67
26	A Higher Proportion of the EGFR T790M Mutation May Contribute to the Better Survival of Patients with Exon 19 Deletions Compared with Those with L858R. Journal of Thoracic Oncology, 2017, 12, 1368-1375.	0.5	79
27	Detection of Driver and Resistance Mutations in Leptomeningeal Metastases of NSCLC by Next-Generation Sequencing of Cerebrospinal Fluid Circulating Tumor Cells. Clinical Cancer Research, 2017, 23, 5480-5488.	3.2	78
28	P3.02b-016 An Exploration Study of Mechanisms Underlying Primary Resistance to EGFR-TKIs in Patients Harboring TKI-Sensitive EGFR Mutations. Journal of Thoracic Oncology, 2017, 12, S1195-S1196.	0.5	0
29	Liquid biopsy in non-small cell lung cancer: a key role in the future of personalized medicine?. Expert Review of Molecular Diagnostics, 2017, 17, 1089-1096.	1.5	16
30	EGFR mutation correlates with uninflamed phenotype and weak immunogenicity, causing impaired response to PD-1 blockade in non-small cell lung cancer. OncoImmunology, 2017, 6, e1356145.	2.1	305
31	A comprehensive review of uncommon EGFR mutations in patients with non-small cell lung cancer. Lung Cancer, 2017, 114, 96-102.	0.9	146
32	Heterogeneity of the resistance to gefitinib treatment in a nonâ€small cell lung cancer patient with active epidermal growth factor receptor mutation. Thoracic Cancer, 2017, 8, 51-53.	0.8	8
33	JCES 01.26 Circulating Cell-Free DNA of Cerebrospinal Fluid May Function as Liquid Biopsy for Leptomeningeal Metastases of ALK Rearrangement NSCLC. Journal of Thoracic Oncology, 2017, 12, S1739.	0.5	0
34	P1.01-018 Acquired Resistance to Crizotinib in Advanced NSCLC with De Novo MET Overexpression. Journal of Thoracic Oncology, 2017, 12, S1899.	0.5	3
35	EGFR mutation in early-stage and advanced-stage lung adenocarcinoma: Based on large date in China. Annals of Oncology, 2017, 28, x120.	0.6	0
36	The role of T790M mutation in EGFR-TKI re-challenge for patients with EGFR-mutant advanced lung adenocarcinoma. Oncotarget, 2017, 8, 4994-5002.	0.8	8

#	Article	IF	Citations
37	Effects of epidermal growth factor receptorâ€tyrosine kinase inhibitors alone on EGFR â€mutant nonâ€small cell lung cancer with brain metastasis. Thoracic Cancer, 2016, 7, 648-654.	0.8	23
38	Serial cfDNA assessment of response and resistance to EGFR-TKI for patients with EGFR-L858R mutant lung cancer from a prospective clinical trial. Journal of Hematology and Oncology, 2016, 9, 86.	6.9	41
39	Clinical outcomes of advanced non-small-cell lung cancer patients with EGFR mutation, ALK rearrangement and EGFR/ALK co-alterations. Oncotarget, 2016, 7, 65185-65195.	0.8	31
40	The coexistence of MET over-expression and an EGFR T790M mutation is related to acquired resistance to EGFR tyrosine kinase inhibitors in advanced non-small cell lung cancer. Oncotarget, 2016, 7, 51311-51319.	0.8	35
41	Symptom and Quality of Life Improvement in LUX-Lung 6: An Open-Label Phase III Study of Afatinib Versus Cisplatin/Gemcitabine in Asian Patients With EGFR Mutation-Positive Advanced Nonâ€“small-cell Lung Cancer. Journal of Thoracic Oncology, 2015, 10, 883-889.	0.5	55
42	Venous thromboembolism risk factors in Chinese non-small cell lung cancer patients. Supportive Care in Cancer, 2015, 23, 635-641.	1.0	19
43	First-line versus second or further-line crizotinib for trial patients with advanced non-small-cell lung cancer harboring ALK rearrangements.. Journal of Clinical Oncology, 2015, 33, e19139-e19139.	0.8	1
44	Feasibility of computed tomographyâ€guided core needle biopsy in producing stateâ€ofâ€theâ€art clinical management in <scp>C</scp>hinese lung cancer. Thoracic Cancer, 2014, 5, 155-161.	0.8	4
45	Lung Cancer Treatment Disparities in China: A Question in Need of an Answer. Oncologist, 2014, 19, 1084-1090.	1.9	18
46	Afatinib versus cisplatin plus gemcitabine for first-line treatment of Asian patients with advanced non-small-cell lung cancer harbouring EGFR mutations (LUX-Lung 6): an open-label, randomised phase 3 trial. Lancet Oncology, The, 2014, 15, 213-222.	5.1	1,740
47	Reduced chemotherapy sensitivity in EGFR-mutant lung cancer patient with frontline EGFR tyrosine kinase inhibitor. Lung Cancer, 2014, 86, 219-224.	0.9	17
48	Prognostic Significance of Genotype and Number of Metastatic Sites in Advanced Nonâ€“Small-Cell Lung Cancer. Clinical Lung Cancer, 2014, 15, 441-447.	1.1	35
49	Pemetrexed versus gefitinib as a second-line treatment in advanced nonsquamous nonsmall-cell lung cancer patients harboring wild-type EGFR (CTONG0806): a multicenter randomized trial. Annals of Oncology, 2014, 25, 2385-2391.	0.6	64
50	A multicenter phase II study of sorafenib monotherapy in clinically selected patients with advanced lung adenocarcinoma after failure of EGFR-TKI therapy (Chinese Thoracic Oncology Group, CTONG) Tj ETQq0 0 0 rgBT /Overlock 10 Tf 50	6.9	44
51	Overall survival in patients with advanced non-small cell lung cancer harboring concomitant EGFR mutations and ALK rearrangements: A cohort study.. Journal of Clinical Oncology, 2014, 32, e19010-e19010.	0.8	1
52	MET overexpression as a promising therapeutic target in non-small cell lung cancer with acquired resistance to EGFR TKIs.. Journal of Clinical Oncology, 2014, 32, e19047-e19047.	0.8	1
53	Clinical modes of EGFR tyrosine kinase inhibitor failure and subsequent management in advanced non-small cell lung cancer. Lung Cancer, 2013, 79, 33-39.	0.9	156
54	Can EGFR-TKIs be used in first line treatment for advanced non-small cell lung cancer based on selection according to clinical factors ? -- A literature-based meta-analysis. Journal of Hematology and Oncology, 2012, 5, 62.	6.9	25

#	Article	IF	Citations
55	Nedaplatin/gemcitabine versus carboplatin/gemcitabine in treatment of advanced non-small cell lung cancer: A randomized clinical trial. Chinese Journal of Cancer Research: Official Journal of China Anti-Cancer Association, Beijing Institute for Cancer Research, 2012, 24, 97-102.	0.7	8
56	Is 18F-fluorodeoxyglucose positron emission tomography-based metabolic response superior to Response Evaluation Criteria In Solid Tumors-based response after two cycles of platinum-based chemotherapy in predicting clinical outcome of untreated patients with advanced non-small cell lung cancer?. Nuclear Medicine Communications, 2011, 32, 1113-1120.	0.5	1
57	Relative Abundance of EGFR Mutations Predicts Benefit From Gefitinib Treatment for Advanced Nonâ€“Small-Cell Lung Cancer. Journal of Clinical Oncology, 2011, 29, 3316-3321.	0.8	233
58	Induction erlotinib therapy in stage IIIA-N2 non-small cell lung cancer.. Journal of Clinical Oncology, 2010, 28, TPS284-TPS284.	0.8	0
59	An Autologous Therapeutic Dendritic Cell Vaccine Transfected with Total Lung Carcinoma RNA Stimulates Cytotoxic T Lymphocyte Responses Against Non-Small Cell Lung Cancer. Immunological Investigations, 2009, 38, 665-680.	1.0	12
60	Docetaxel as salvage chemotherapy in patients with advanced non-small cell lung cancer after failure of cytotoxic agents and gefitinib treatment. Chinese-German Journal of Clinical Oncology, 2008, 7, 495-499.	0.1	1
61	D3-05: Prediction of best objective response and survival to the first-line chemotherapy in advanced non-small cell lung cancer by 18FDG-PET. Journal of Thoracic Oncology, 2007, 2, S398.	0.5	0
62	P2-151: Change of the EGFR expression and downstream signal pathway in A549 cell Treated with ZD1839. Journal of Thoracic Oncology, 2007, 2, S551.	0.5	0
63	P3-110: Tumor histology and N-score predict survival with gefitinib in patients with advanced non-small cell lung cancer. Journal of Thoracic Oncology, 2007, 2, S726.	0.5	0
64	P2-053: Establishment, identification and examination about the EGFR status of the lung cancer cell line. Journal of Thoracic Oncology, 2007, 2, S511.	0.5	0